Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 9/20 | 0.68 |
| ▸ | PDE5A | O76074 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TNKS | O95271 | 4/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.54 |
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1084872 | 0.85 | GUSB (0.78) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL29740691 | 0.85 | GUSB (0.78) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL11375677 | 0.83 | PDE5A (0.54) | GUSBPDE5AKDM4EHPGDTNKS | |
| SCHEMBL13604403 | 0.82 | GUSB (0.69) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL11380795 | 0.81 | PDE5A (0.55) | GUSBPDE5AKDM4EHPGDTNKS | |
| SCHEMBL7160589 | 0.81 | GUSB (1.00) | GUSBPDE5AKDM4EHPGD | |
| SCHEMBL31238756 | 0.81 | GUSB (1.00) | GUSBPDE5AKDM4EHPGD | |
| SCHEMBL4579539 | 0.81 | GUSB (0.67) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL14845878 | 0.80 | GUSB (0.63) | GUSBKDM4EHPGDTNKSTNKS2 | |
| SCHEMBL297069 | 0.80 | GUSB (0.67) | GUSBPDE5AKDM4EHPGDTNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MOLECULAR PROBES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MOLECULAR PROBES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160139135-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | LIFE TECHNOLOGIES CORP (US) | 2016-05-19 | — | — | US | disclosed |
| US-8865891-B2 | Optically-detectable enzyme substrates and their method of use | Life Technologies Corporation (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130090470-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | Life Technologies Corporation (US) | 2013-04-11 | — | — | US | disclosed |
| US-8318450-B2 | Optically-detectable enzyme substrates and their method of use | Life Technologies Corporation (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318450-B2 | Optically-detectable enzyme substrates and their method of use | Life Technologies Corporation (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120040380-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | Life Technologies Corporation (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040380-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | Life Technologies Corporation (US) | 2012-02-16 | — | — | US | disclosed |
| US-20090047692-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | INVITROGEN CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047692-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | INVITROGEN CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160139135-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MGAM, LCT, GAA | GUSB 22/4885PDE5A 936/4885KDM4E 3086/4885 |
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MGAM, LCT, GAA | GUSB 22/4885PDE5A 936/4885KDM4E 3086/4885 |
| US-20130090470-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | MGAM, LCT, GAA | GUSB 22/4885PDE5A 936/4885KDM4E 3086/4885 |
| US-20090047692-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | MGAM, LCT, GAA | GUSB 22/4885PDE5A 936/4885KDM4E 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.